ClinicalTrials.gg
CompletedNCT00399230Updated Aug 21, 2007

A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye

A Phase 4 interventional study of Optive in Dry Eye, sponsored by Innovative Medical. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-08-21.

Sponsored by Innovative Medical · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. carboxymethylcellulose · Dry Eye Syndromes.

Phase 4
11 of 12
2 open now
Registered
3rd of 12
by date
Lead sponsor
2 of 12
Innovative Medical

Among the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, this one is one of 11 in phase 4, and was the 3rd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About carboxymethylcellulose

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, or all of them as a file.
02

Study summary

To evaluate the effectiveness of NGT (Optive) vs. Systane Tears for patients with moderate to severe dry eye disease.

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Dry eye disease diagnosis

      • Patients must currently be using Systane tears at least once a day and for at least 1 month.
      • Normal lid position and closure
      • Male or female of legal age of consent
      • has been obtained
      • Likely to complete all required follow-up visits

Exclusion criteria

Exclusion Criteria:

    • Concurrent enrollment in an drug or device study, or participation in such a study within 30 days of entry into this study.

      • Subject has a condition, or is in a situation which, in the investigator's opinion, may put the subject at a significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)

Interventions

06

Study locations

1 site
  • Dr. Rajpal
    McLean, Virginia 22102, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00399230
Lead sponsor
Innovative Medical
First posted
Nov 14, 2006
Last update
Aug 21, 2007

Study contacts

Rajesh Rajpal, MD
principal investigator · See Clearly Vision Group
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboxymethylcellulose · Glycerol

Start the discussion